Bexarotene

Generic Name: Bexarotene

Brand Names: Targretin

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈O_₂

CAS Number: 153559-49-0

Unique Ingredient Identifier: A61RXM4375

Background: Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

Indication: 用于全身治疗无效的皮肤Ｔ细胞淋巴癌（CTCL）。

Associated Conditions: Refractory Cutaneous T-cell Lymphoma

Associated Therapies: -

Clinical Trials

Bexarotene in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-05-25

Last Posted Date: 2013-05-30

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 180

Registration Number: NCT00003752

Locations: 🇺🇸
Baptist Regional Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee, United States
🇺🇸
Louisiana State University School of Medicine, New Orleans, Louisiana, United States

and more 27 locations

Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides

Phase 3

Terminated

Conditions: Lymphoma

Interventions: Drug: bexarotene
Drug: methoxypsoralen
Procedure: UV light therapy

First Posted Date: 2003-03-07

Last Posted Date: 2018-07-09

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 93

Registration Number: NCT00056056

Locations: 🇫🇷
CHR Hotel Dieu, Nantes, France
🇪🇸
Hospital Universitari de Bellvitge, Barcelona, Spain
🇦🇹
Allgemeines Krankenhaus - Universitatskliniken, Vienna, Austria

and more 25 locations

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: bexarotene

First Posted Date: 2003-03-07

Last Posted Date: 2013-02-05

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 87

Registration Number: NCT00055991

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States

and more 1 locations

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Millennix

Registration Number: NCT00030589

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States

and more 14 locations

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00030849

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

and more 2 locations

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2003-01-03

Last Posted Date: 2013-05-14

Lead Sponsor: Eisai Inc.

Target Recruit Count: 623

Registration Number: NCT00050973

Locations: 🇬🇧
Guys & St. Thomas' Cancer Centre, London, England, United Kingdom
🇨🇦
Cancer Care Manitoba, Winnepeg, Manitoba, Canada
🇺🇸
University Oncology & Hematology Associates, Chattanooga, Tennessee, United States

and more 74 locations

A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma

Phase 2

Completed

Conditions: Sarcoma, Kaposi
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT00002212

Locations: 🇺🇸
Tulane Univ School of Medicine, New Orleans, Louisiana, United States
🇺🇸
Desert Univ School of Medicine, Palm Springs, California, United States
🇺🇸
Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy